1-2 of 2 results for subject:Pfizer
Librarians' tools
- Search time
- 0.643 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Year
X
2007
Type
House
Session
Month
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health what assessment he has made of the impact of the changes in distribution of Pfizer medicines on NHS patients.
To ask the Secretary of State for Health what assessment he has made of the impact of the changes in distribution of Pfizer medicines on NHS patients.
Asked by
Sandra Gidley
(Liberal Democrat)
Answered by
Baroness Primarolo
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
3 July 2007
For answer on
5 July 2007
Answered on
10 July 2007
Officials in the Department continue to monitor the operation of the new arrangements. No substantial problems have been reported and no corrective action has had to be taken.
Subjects
Drugs; NHS; Pfizer
Date
10 July 2007
Reference
147982; 462 c1453W;462 c1452W
House
House of Commons
Type
House of Commons papers; Select Committee written evidence;
Parliamentary committees
Committee
Health Committee
Notes
Report printed as HC 27 2007-08
Subjects
Assessments; Companies; Cost effectiveness; Finance; Licensing; Drugs; NHS; Medical treatments; Patients; Prescription drugs; Public expenditure; Primary care trusts; Prices; National Institute for Health and Care Excellence; Standards; Technology; British Medical Association; Pfizer; Alzheimer's Society; National Osteoporosis Society; Multiple Sclerosis Society; Clinical trials; Royal College of Nursing; Bioindustry Association; British Psychological Society; Cancer Research UK; Diabetes UK; Hepatitis C Trust; British Association for Counselling and Psychotherapy; Help the Aged; Motor Neurone Disease Association; Royal College of Midwives; Amgen Roche; Association of British Healthcare Industries; AstraZeneca; Arthritis and Musculoskeletal Alliance; Breakthrough Breast Cancer; Cancerbackup; Continence Foundation; Cystic Fibrosis Trust; JEC; Medical Technology Group; National Infertility Awareness Campaign; National Childbirth Trust; Myalgic Encephalomyelitis Association; National Rheumatoid Arthritis Society; Royal College of Paediatrics and Child Health; Roche; Sanofi-Aventis; Wyeth; Academy of Medical Sciences; Roy Castle Lung Cancer Foundation; Specialised Healthcare Alliance; Medtronic; American Pharmaceutical Group; Archimedes Pharma; Beat; Bayer Schering Pharma; British Society for Rheumatology; Bristol Myers Squibb Pharmaceuticals; Deltex Medical; Eli Lilly; European Medicines Group; Ethical Medicines Industry Group; FEmISA; Improving Surgical Outcomes Group; Institute for Innovation and Valuation in Health Care; Kidney Cancer UK; Kinetic Concepts; Leukaemia Care; Merck; Myeloma UK; Pelvic Pain Support Network; Rarer Cancers Forum; Royal College of Physicians of Edinburgh; Sirtex Medical; Servier Laboratories; 25% ME Group; Meads, Catherine; Bouder, Frederic; Barkham, Michael; Lofstedt, Ragnar; Simkin, Sandra; Austin, Daphne; Jones, Doris; Hooper, Malcolm; Chalmers, Iain; Hyde, Chris; Lee, Gay; Evans, Imogen; Marshall, Tom; Lee, Michael; Telford, Peter; Walsh, John; Syrett, Keith; Thornton, Hazel; Thomson, David; Woodward, Rose
Date
26 April 2007
Reference
HC 503 2006-07
House
House of Commons